SearchDictionaryMobileLogin

S 1 (combination)

Subscribe to Selected New Research on S 1 (combination)
20  relevant articles (5 outcomes, 10 trials/studies) found for this Bio-Agent

Description: consists of tegafur, 5-chloro-2,4-dihydroxyuridine & potassium oxonate; an inhibitor of fluorouracil(5-FU) degradation; prolongs the blood 5-FU level as well as increases selective toxicity to tumor; used for the treatment of colon cancer

Also Known As:
BMS 247616; BMS247616; S-1 (combination); S-1 cpd; S1-fluoropyrimidine oxoonate combination; S1-tegafur-oxonate combination; TS-1 cpd

Relationship Network

Bio-Agent Context: Research Results

-
Heterocyclic Compounds: 25
-
1-Ring Heterocyclic Compounds
-
Pyrimidines: 281
-
Pyrimidinones: 14
-
Uracil: 924
-
Fluorouracil: 14843
-
Tegafur: 1098
*
S 1 (combination): 20
-
Triazines: 28
-
Oxonic Acid: 52
*
S 1 (combination): 20
-
Pharmaceutical Preparations
-
Drug Combinations: 850
*
S 1 (combination): 20

Experts

1. Aridome, Kuniaki: 2 articles (11/2008 - 12/2007)
2. Aikou, Takashi: 2 articles (11/2008 - 12/2007)
3. Ishigami, Sumiya: 2 articles (11/2008 - 12/2007)
4. Hokita, Shuichi: 2 articles (11/2008 - 12/2007)
5. Natsugoe, Shoji: 2 articles (11/2008 - 12/2007)
6. Hamanoue, Masahiro: 1 article (11/2008)
7. Maenohara, Shigeho: 1 article (11/2008)
8. Morita, Satoshi: 1 article (11/2008)
9. Satoh, Kiyoharu: 1 article (11/2008)
10. Takiuchi, Hiroya: 1 article (11/2008)

Related Diseases

1. Stomach Neoplasms (Stomach Cancer)
2. Neoplasm Metastasis (Metastasis)
3. Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2008 - "The GEM/S-1 combination therapy in patients with pancreatic cancer may be promising and should be tested in clinical trials."
01/01/2008 - "The purpose of this study was to evaluate the relationship between different schedules and the effects of GEM/S-1 combination therapy on pancreatic cancer xenograft models. "
04/01/2008 - "Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer."
01/01/2008 - "The studies discussed here include the following: i) a phase I study of a chemotherapy doublet gemcitabine plus capecitabine, combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma (abstract #141); ii) a phase II study of gemcitabine, bevacizumab, and erlotinib in locally advanced and metastatic adenocarcinoma of the pancreas (abstract #151); iii) final results of the multicenter phase II study on gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (abstract #198); iv) interim results from a phase II study of volociximab in combination with gemcitabine in patients with metastatic pancreatic cancer (abstract #142); v) a pilot study of combination chemotherapy with S-1 and irinotecan for advanced pancreatic cancer (abstract #155); vi) a multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer (abstract #212); vii) a phase I/II study of PHY906 plus capecitabine in patients with advanced pancreatic carcinoma (abstract #260); and viii) the final results of a phase II trial of Genexol-PM(R), a novel cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (abstract #269). "
Order ALL the reference details at left...
4. Adenocarcinoma
12/01/2007 - "The successfully curative treatment of advanced gastric adenocarcinoma with multiple liver metastases and paraaortic lymph node metastases by salvage operation following the biweekly paclitaxel and S-1 combination chemotherapy: a case report."
01/01/2008 - "The studies discussed here include the following: i) a phase I study of a chemotherapy doublet gemcitabine plus capecitabine, combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma (abstract #141); ii) a phase II study of gemcitabine, bevacizumab, and erlotinib in locally advanced and metastatic adenocarcinoma of the pancreas (abstract #151); iii) final results of the multicenter phase II study on gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (abstract #198); iv) interim results from a phase II study of volociximab in combination with gemcitabine in patients with metastatic pancreatic cancer (abstract #142); v) a pilot study of combination chemotherapy with S-1 and irinotecan for advanced pancreatic cancer (abstract #155); vi) a multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer (abstract #212); vii) a phase I/II study of PHY906 plus capecitabine in patients with advanced pancreatic carcinoma (abstract #260); and viii) the final results of a phase II trial of Genexol-PM(R), a novel cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (abstract #269). "
Order ALL the reference details at left...
5. Colorectal Neoplasms (Colorectal Cancer)

Related Drugs and Biologics

1. docetaxel (Taxotere)
2. Cisplatin (Platino)
3. irinotecan (Camptosar)
4. Paclitaxel (Taxol)
5. gemcitabine
6. DNA (Deoxyribonucleic Acid)
7. volociximab
8. PHY 906
9. bevacizumab
10. erlotinib (CP 358,774)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Gastrectomy
3. Heterologous Transplantation (Xenotransplantation)
4. Combination Drug Therapy (Combination Chemotherapy)
5. Adjuvant Chemotherapy

Best Treatments:
Research Summary Report
on Stomach Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 898 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>